Benzinga
23 Sept 2025, 15:32 UTC · 51w ago
Verdict
Headline leans bearish. We score SRRK −0.60 across four claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.60strongly bearish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The FDA issued a Complete Response Letter (CRL) delaying the approval of Scholar Rock's apitegromab for spinal muscular atrophy.
More negative than 92% of claims this week
Regeneron Pharmaceuticals expects regulatory delays for its EYLEA HD applications due to the same FDA observations at the Catalent Indiana facility.
So whatThis indicates a systemic manufacturing issue affecting multiple high-value biotech pipelines, increasing risk for any company relying on this facility.
Continue reading
5 related stories
More negative than 82% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 80% of claims this week
The FDA delay for apitegromab is based on site inspection issues at Catalent Indiana and is not related to the drug's safety or efficacy.
More positive than 65% of claims this week
Scholar Rock's marketing authorization application for apitegromab is still under review by the European Medicines Agency with a decision expected by mid-2026.
More positive than 45% of claims this week
Which stocks this story touches
More negative than 82% of ticker scores this week
The FDA issued a Complete Response Letter delaying the approval of its SMA drug apitegromab.
More negative than 79% of ticker scores this week
The company expects regulatory approval delays for its EYLEA HD applications due to issues at the Catalent Indiana facility.
More negative than 70% of ticker scores this week
A facility it acquired, Catalent Indiana, is facing FDA inspection observations causing drug delays for multiple partners.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
13h ago
More positive than 34% of relationship scores this week
[a_to_b] Novo Nordisk's acquired facility (Catalent Indiana) serves as the third-party fill-finish facility for Scholar Rock.
+51.5%
Price is moving against the score
$49.37 vs $32.58 close before publication (Sep 22) · not market-adjusted
SRRK chart →
